Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43876   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005206-10
    Sponsor's Protocol Code Number:PR200-104
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-03-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-005206-10
    A.3Full title of the trial
    A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)
    Studio in doppio cieco, randomizzato, controllato con placebo volto a valutare l'efficacia e la sicurezza di PRA023 in soggetti affetti da sclerosi sistemica associata a malattia polmonare interstiziale (SSc-ILD)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease
    Studio di PRA023 in soggetti affetti da sclerosi sistemica associata a malattia polmonare interstiziale (SSc-ILD)
    A.3.2Name or abbreviated title of the trial where available
    The ATHENA-SSc-ILD Study
    Studio ATHENA-Ssc-ILD
    A.4.1Sponsor's protocol code numberPR200-104
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPrometheus Biosciences Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPrometheus Biosciences, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPrometheus Biosciences, Inc.
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street Address9410 Carroll Park Drive
    B.5.3.2Town/ citySan Diego
    B.5.3.3Post codeCA 92121
    B.5.3.4CountryUnited States
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailAthenaMM@prometheusbiosciences.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code [PRA023]
    D.3.4Pharmaceutical form Concentrate for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codePRA023
    D.3.9.3Other descriptive namePRA023
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Systemic sclerosis associated with interstitial lung disease
    Sclerosi sistemica associata a malattia polmonare interstiziale
    E.1.1.1Medical condition in easily understood language
    Systemic sclerosis is a disease characterized by abnormal and excess fibrosis, a hardening of tissues and organs.
    La sclerosi sistemica è una malattia caratterizzata da fibrosi anormale ed eccessiva, un indurimento di tessuti e organi.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10025109
    E.1.2Term Lung involvement in systemic sclerosis
    E.1.2System Organ Class 100000004855
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To assess the safety and tolerability of PRA023 in SSc-ILD
    • To compare the annual rate of change from Baseline in forced vital capacity (FVC), in mL, of PRA023 vs. placebo over 50 weeks
    • Valutare la sicurezza e la tollerabilità di PRA023 nella SSc-ILD
    • Confrontare il tasso annuale di variazione dal Basale nella capacità vitale forzata (FVC), in ml, di PRA023 vs. placebo nell'arco di 50 settimane
    E.2.2Secondary objectives of the trial
    • To compare the change from Baseline in FVC in mL of PRA023 vs. placebo at Week 50
    • To compare the change from Baseline in FVC in percent predicted of PRA023 vs. placebo at Week 50
    • To compare the annual rate of change in percent predicted FVC
    • To compare proportion of subjects with an improvement in the American College of Rheumatology Combined Response Index in Systemic Sclerosis (ACR CRISS) score at Week 50
    • Confrontare la variazione dal Basale nella FVC, in ml, di PRA023 vs. placebo alla Settimana 50
    • Confrontare la variazione dal Basale nella FVC, in percentuale prevista, di PRA023 vs. placebo alla Settimana 50
    • Confrontare il tasso annuo di variazione della percentuale di FVC prevista
    • Confrontare la percentuale di soggetti con un miglioramento in 3 o più degli 5 indicatori "core" del punteggio dell'indice di risposta combinato per la sclerosi sistemica dell'American College of Rheumatology (ACR CRISS) di PRA023 rispetto al placebo alla Settimana 50
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Skin Biopsy Substudy: to assess change in histology and protein expression
    Pharmacokinetic Substudy: Fully characterize PK of PRA023 in subjects with SSc-ILD

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Skin Biopsy Substudy: to assess change in histology and protein expression
    Pharmacokinetic Substudy: Fully characterize PK of PRA023 in subjects with SSc-ILD
    E.3Principal inclusion criteria
    1. Confirmed diagnosis of systemic sclerosis with onset of disease < or =5 years ago
    2. Diffuse cutaneous scleroderma
    3. Systemic sclerosis related to interstitial lung disease confirmed by HRCT
    4. FVC > or = 45% of predicted normal
    5. Diffusing capacity of lung for carbon monoxide (DLCO) > or = 45% of predicted normal
    6. Stable dosing of myocphenolate mofetil (MMF), methotrexate (MTX) or azathioprine, as well as corticosteroids
    7. Able to provide written informed consent and understand and comply with the requirements of the study
    1. Confermata insorsgenza di SSc < o = 5 anni prima
    2. Sclerodermia cutanea diffusa
    3. SSc come malattia fibrotica dei polmoni confermata mediante HRCT
    4. FVC > o = 45% rispetto al valore normale previsto.
    5. Capacità di diffusione polmonare del monossido di carbonio (DLCO) > o = 45% rispetto al valore normale previsto
    6. Dosaggi stabili di Micofenolato mofetile , metotrexato, azatioprina e corticosteroidi
    7. Fornire il consenso informato scritto e comprendere e rispettare i requisiti dello studio
    E.4Principal exclusion criteria
    1. WOCBP and men with female partners of childbearing potential who are unwilling or unable to use two highly effective methods of contraception to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of study drug.
    2. Airway obstruction per pulmonary function test (PFT) or Clinically significant pulmonary arterial hypertension.
    3. Current clinical diagnosis of another inflammatory connective tissue disease
    disease
    4. Any active infections, a serious infection within the past 3 months, or chronic bacterial infection
    5. Current smoker or smoking within 6 months of screening
    6. Subjects in the opinion of the investigator that are at an unacceptable risk for participation in the study
    7. Subjects who meet the protocol criteria for important laboratory exclusion criteria
    1. WOCBP e uomini con partner di sesso femminile in età fertile che non sono disposti o non sono in grado di usare due metodi contraccettivi altamente efficaci per evitare la gravidanza per l'intero periodo dello studio e fino a 12 settimane dopo l'ultima dose del farmaco in studio.
    2. Ostruzione delle vie aeree (PFT) o Ipertensione arteriosa polmonare (PAH) clinicamente significativa.
    3. Attuale diagnosi clinica di un'altra malattia infiammatoria del tessuto connettivo (
    4. Qualsiasi infezione attiva, un'infezione grave negli ultimi 3 mesi o un'infezione batterica cronica
    5. Fumatore attuale o fumatore entro 6 mesi dallo screening
    6. Soggetti a giudizio dello sperimentatore che corrono un rischio inaccettabile per la partecipazione allo studio
    7. Soggetti che soddisfano i criteri del protocollo per importanti criteri di esclusione di laboratorio
    E.5 End points
    E.5.1Primary end point(s)
    • The proportion of subjects reporting adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and markedly abnormal laboratory values
    • To compare the annual rate of change from Baseline in FVC, in mL, of PRA023 vs. placebo over 50 weeks
    • Proporzione di soggetti che riferiscono eventi avversi (AE), eventi avversi seri (SAE), AE che portano all'interruzione del trattamento e valori di laboratorio marcatamente anomali
    • Confrontare il tasso annuale di variazione dal Basale nella FVC, in ml, di PRA023 vs. placebo nell'arco di 50 settimane
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 50
    Settimana 50
    E.5.2Secondary end point(s)
    • To compare the change from Baseline in FVC
    • To compare the annual rate of change in percent FVC
    • To compare the change from Baseline in HRCT
    • To compare proportion of subjects with an improvement of the ACR CRISS score
    • Confrontare la variazione dal Basale nella FVC
    • Confrontare il tasso annuale di variazione nella FVC, in percentuale prevista
    • Confrontare la variazione dal Basale nella HRCT
    • Confrontare la percentuale di soggetti con un miglioramento del punteggio ACR CRISS
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 50
    Settimana 50
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA39
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    United States
    Belgium
    France
    Germany
    Hungary
    Italy
    Norway
    Poland
    United Kingdom
    Netherlands
    Spain
    Switzerland
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 61
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who complete the 50-week Treatment Period, irrespective of treatment assignment, will have the option to enter OLE starting at Week 54 visit, contingent upon the analysis of emerging safety and efficacy data in this patient population.
    Subjects who complete the 50-week Treatment Period, irrespective of treatment assignment, will have the option to enter OLE starting at Week 54 visit, contingent upon the analysis of emerging safety and efficacy data in this patient population.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-05-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-07-19
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 11 14:32:15 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA